Key Takeaways:
MiMedx Group Inc. agreed to buy Sanara MedTech for $35 a share, or about $350 million, as it reported second-quarter net sales of $64 million.
"This transformational combination will immediately create one of the largest regenerative medicine companies across numerous surgical subspecialties," Chief Executive Officer Joe Capper said.
Sanara shareholders will receive $33 in cash and 0.4735 MiMedx shares for each share they own, a 46 percent premium to the 30-day volume-weighted average price. MiMedx expects the combined company to generate revenue well in excess of $400 million in 2027, with at least $20 million in annualized cost savings and an adjusted EBITDA margin of at least 20 percent.
The acquisition shifts MiMedx's revenue mix toward surgery, with about 75 percent of revenue expected from surgical products after closing. MiMedx secured a $300 million term loan from Hayfin Capital Management to finance the cash portion and expects the deal to close by year-end.
MiMedx reported a net loss of $15 million for the quarter, compared with net income of $10 million a year earlier. Adjusted gross margin was 74 percent, while reported gross margin fell to 69 percent from 81 percent, driven by Medicare reimbursement changes that took effect Jan. 1.
Surgical product sales rose 15 percent year over year to $39 million, led by AmnioFix and AmnioEffect. Wound-care sales declined 61 percent to $25 million but improved 11 percent sequentially, with volume in wound-care centers jumping 44 percent.
Sanara contributes more than $100 million in annual revenue, all from surgical procedures, and brings products complementary to MiMedx's portfolio. Its largest product, CellerateRX, generated about $80 million in trailing-12-month revenue and is approved in more than 4,000 hospitals. Sanara is also developing OsStic, a synthetic injectable bone bioadhesive with FDA breakthrough device designation that could reach the market in the first quarter of 2027.
MiMedx reiterated its standalone 2026 outlook for net sales between $260 million and $290 million, with adjusted EBITDA approaching breakeven for the full year. The company ended the quarter with $119 million in net cash.
The acquisition gives MiMedx a dominant position in surgical regenerative medicine and diversifies its revenue away from the challenged wound-care segment. Investors will watch for Sanara shareholder approval and regulatory clearance, with the deal expected to close by the end of 2026.
This article is for informational purposes only and does not constitute investment advice.
